Anti-Müllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies

Oncologist

Volumn 18, Issue 12, 2013, Pages 1307-1314

  Di Paola, Rossana ^a,c   Costantini, Claudio ^b,c   Tecchio, Cristina ^b   Salvagno, Gian Luca ^a   Montemezzi, Rachele ^b   Perandini, Alessio ^a   Pizzolo, Giovanni ^b   Zaffagnini, Stefano ^a,c   Franchi, Massimo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Tethys Centre for Reproductive Medicine   (Italy)

Author keywords

Anti M llerian hormone; Antral follicle count; Fertility preservation; Hematological malignancies

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; FOLLITROPIN; IDARUBICIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR; PREDNISONE; RETINOIC ACID; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMALE FERTILITY; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARIAN RESERVE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

ANTI-MÜLLERIAN HORMONE; ANTRAL FOLLICLE COUNT; FERTILITY PRESERVATION; HEMATOLOGICAL MALIGNANCIES;

ADOLESCENT; ANTI-MULLERIAN HORMONE; CASE-CONTROL STUDIES; FEMALE; FERTILITY PRESERVATION; HEMATOLOGIC NEOPLASMS; HUMANS; INHIBIN-BETA SUBUNITS; OVARIAN FOLLICLE; OVARY; SURVIVORS; YOUNG ADULT;

EID: 84890090440     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0138     Document Type: Article

References (40)

1. Lee SJ, Schover LR, Partridge AH et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
2. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 2006;24:1045-1051.
3. Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr 2005:21-25.
4. Meirow D, Biederman H, Anderson RA et al. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol 2010;53:727-739.
5. Buyuk E, Seifer DB, Younger J et al. Random antiMullerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertil Steril 2011;95:2369-2372.
6. Bath LE, Wallace WH, Shaw MP et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: Detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18:2368-2374.
7. Sant M, Allemani C, Tereanu C et al. Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood 2010;116:3724-3734.
8. Lichtman MA. Battling the hematological malignancies: The 200 years' war. The Oncologist 2008; 13:126-138.
9. Behringer K, Mueller H, Goergen H et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31:231-239.
10. Lo-Coco F, Avvisati G, Vignetti M et al. Frontline treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010;116:3171-3179.
11. Dillman RO, Davis RB, Green MR et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-2526.
12. Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 1982;96:139-143.
13. Hoppe RT, Advani RH, Ai WZ et al. Hodgkin lym-phoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10: 589-597.
14. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three inten- sive chemotherapy regimens for advanced nonHodgkin's lymphoma. N Engl J Med 1993;328: 1002-1006.
15. O'Reilly SE, Hoskins P, Klimo P et al. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 2(suppl 1):17-23.
16. Thomas DA, Cortes J, O'Brien S et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-2470.
17. Gianni AM, Siena S, Bregni M et al. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease-a 6-year update. Ann Oncol 1993;4:889-891.
18. Green DM, Kawashima T, Stovall M et al. Fertility of female survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol 2009;27:2677-2685.
19. La Marca A, Spada E, Sighinolfi G et al. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil Steril 2011;95:684-688.
20. Meirow D, Dor J. Epidemiology and infertility in cancer patients. In: Tulandi T, Gosden R, eds. Preservation of fertility. London, UK: Taylor & Francis 2004;21-38.
21. Donnez J, Kim SS. Principles and practice of fertility preservation. Cambridge, UK: Cambridge University Press 2011;18, 517.
22. Harel S, Ferme C, Poirot C. Management of fertility in patients treated for Hodgkin's lymphoma. Haematologica 2011;96:1692-1699.
23. Faddy MJ, Gosden RG. A mathematical model of follicle dynamics in the human ovary. Hum Reprod 1995;10:770-775.
24. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000; 169:123-131.
25. Decanter C, Morschhauser F, Pigny P et al. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: Preliminary results. Reprod Biomed Online 2010;20:280-285.
26. Behringer K, Breuer K, Reineke T et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555-7564.
27. Elis A, Tevet A, Yerushalmi R et al. Fertility status among women treated for aggressive nonHodgkin's lymphoma. Leuk Lymphoma 2006;47: 623-627.
28. Jadoul P, Donnez J. How does bone marrow transplantation affect ovarian function and fertility? Curr Opin Obstet Gynecol 2012;24:164-171.
29. Sanders JE, Hawley J, Levy W et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87:3045-3052.
30. Salooja N, Szydlo RM, Socie G et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: A retrospective survey. Lancet 2001;358:271-276.
31. Spinelli S, Chiodi S, Bacigalupo A et al. Ovarian recovery after total body irradiation and allogeneic bone marrow transplantation: Long-term follow up of 79 females. Bone Marrow Transplant 1994;14: 373-380.
32. Brice P, Haioun C, Andre M et al. Pregnancies after high-dose chemotherapy and autologous stem cell transplantation in aggressive lymphomas. Blood 2002;100:736.
33. Weenen C, Laven JS, Von Bergh AR et al. Anti-Mullerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10:77-83.
34. van Rooij IA, Tonkelaar I, Broekmans FJ et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004;11:601-606.
35. Nelson SM, Yates RW, Fleming R. Serum antiMullerian hormone and FSH: Prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 2007;22:2414-2421.
36. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113-130.
37. Gracia CR, Sammel MD, Freeman E et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97:134-140.e1.
38. Mazonakis M, Damilakis J, Varveris H et al. Therapeutic external irradiation in women of reproductive age: Risk estimation of hereditary effects. Br J Radiol 2004;77:847-850.
39. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003;18:117-121.
40. Brusamolino E, Baio A, Orlandi E et al. Longterm events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res 2006;12:6487-6493.